Nuvectis Pharma, Inc. (NVCT)
21.14
-0.78
(-3.56%)
USD |
NASDAQ |
Oct 05, 13:42
Nuvectis Pharma Net Income (Quarterly) : -7.02M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.02M |
| March 31, 2026 | -6.05M |
| December 31, 2025 | -7.314M |
| September 30, 2025 | -9.891M |
| June 30, 2025 | -6.334M |
| March 31, 2025 | -5.332M |
| December 31, 2024 | -6.248M |
| September 30, 2024 | -4.153M |
| June 30, 2024 | -4.428M |
| March 31, 2024 | -4.171M |
| December 31, 2023 | -6.622M |
| Date | Value |
|---|---|
| September 30, 2023 | -5.881M |
| June 30, 2023 | -5.708M |
| March 31, 2023 | -4.049M |
| December 31, 2022 | -6.696M |
| September 30, 2022 | -5.877M |
| June 30, 2022 | -3.569M |
| March 31, 2022 | -2.943M |
| December 31, 2021 | -2.261M |
| September 30, 2021 | -4.668M |
| June 30, 2021 | -5.938M |
| March 31, 2021 | -0.023M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Opus Genetics, Inc. | -8.098M |
| Faeth Therapeutics, Inc. | -16.01M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 7.02M |
| EPS Diluted (Quarterly) | -0.299 |
| Enterprise Value | 562.99M |
| Earnings Yield | -6.04% |
| Normalized Earnings Yield | -6.044 |